secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001558370-25-007664
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO Q1 net loss $8.9M; cash $42.2M; KPI-012 Phase 2b topline data due Q3 2025
--------------------------------------------------------------------------------

- Cash and cash equivalents of $42.2M as of March 31, 2025, expected to fund operations into Q1 2026.
- Q1 2025 net loss $8.9M ($1.41 per diluted share) vs $11.8M ($4.20) prior year; operating loss $10.7M.
- G&A $4.6M (down from $5.4M); R&D $6.1M (down from $6.4M). Weighted shares 6.3M vs 2.8M.
- Phase 2b CHASE trial of KPI-012 in PCED continues enrolling; topline data anticipated in Q3 2025.
- Exploring KPI-012 for Limbal Stem Cell Deficiency; preclinical KPI-014 for inherited retinal diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/0001558370-25-007664-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/kala-20250514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007664

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer